Workflow
IRAY TECHNOLOGY(688301)
icon
Search documents
奕瑞科技(688301) - 奕瑞科技关于“奕瑞转债”跟踪信用评级结果的公告
2025-06-23 11:17
本次债券评级:公司主体信用等级为"AA",评级展望为"稳定","奕瑞 转债"的信用等级为"AA"。 | 证券代码:688301 | 证券简称:奕瑞科技 | 公告编号:2025-044 | | --- | --- | --- | | 转债代码:118025 | 转债简称:奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于"奕瑞转债"跟踪信用评级结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 前次债券评级:公司主体信用等级为"AA",评级展望为"稳定","奕瑞 转债"的信用等级为"AA"。 1 特此公告。 根据《上市公司证券发行注册管理办法》《上海证券交易所科创板股票上市 规则》等有关规定,奕瑞电子科技集团股份有限公司(以下简称"公司")委托 信用评级机构东方金诚国际信用评估有限公司(以下简称"东方金诚")对公司 向不特定对象发行的可转换公司债券(以下简称"奕瑞转债")进行了跟踪信用 评级。 公司前次主体信用等级为"AA",评级展望为"稳定","奕瑞转债"的信用 等级为"AA",评级机构为东方金诚, ...
奕瑞科技:股东询价转让价格为75.86元/股
news flash· 2025-06-23 11:01
奕瑞科技公告,根据2025年6月23日询价申购情况,初步确定的股东询价转让转让价格为75.86元/股。 受让方通过询价转让受让的股份,在受让后6个月内不得转让。参与本次询价转让报价的机构投资者共 29家,合计有效认购股份数量为1164万股,对应的有效认购倍数约为1.9倍。本次询价转让拟转让股份 已获全额认购,初步确定受让方为22家机构投资者,拟受让股份总数为612.24万股。 ...
上证科创板医疗指数报697.06点,前十大权重包含奕瑞科技等
Sou Hu Cai Jing· 2025-06-23 09:03
Core Viewpoint - The Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index has shown a decline in performance over various time frames, indicating potential challenges in the medical sector within the Sci-Tech Innovation Board [1][2]. Group 1: Index Performance - The Shanghai Sci-Tech Innovation Board Medical Index reported a value of 697.06 points, with a decline of 4.19% over the past month, 7.99% over the past three months, and 3.88% year-to-date [1]. - The index is composed of no more than 30 listed companies in the medical field, reflecting the overall performance of medical stocks on the Sci-Tech Innovation Board, with a base date of December 30, 2022, set at 1000.0 points [1]. Group 2: Index Holdings - The top ten weighted companies in the index include: Huatai Medical (10.77%), United Imaging (10.14%), Yirui Technology (7.2%), Aibo Medical (6.29%), Rejing Biology (5.94%), Nanwei Medical (4.99%), Shengxiang Biology (4.84%), Xinmai Medical (4.35%), Haier Biology (3.92%), and Yahui Long (3.41%) [1]. - The index is exclusively composed of companies listed on the Shanghai Stock Exchange, with the industry breakdown showing that medical consumables account for 42.66%, medical devices for 30.80%, and in vitro diagnostics for 26.54% [2]. Group 3: Index Adjustment Mechanism - The index samples are adjusted quarterly, with implementation occurring on the next trading day following the second Friday of March, June, September, and December [2]. - Weight factors are adjusted in accordance with the sample changes, and in special circumstances, the index may undergo temporary adjustments [2].
奕瑞科技: 中国国际金融股份有限公司关于奕瑞电子科技集团股份有限公司股东向特定机构投资者询价转让股份相关资格的核查意见
Zheng Quan Zhi Xing· 2025-06-20 13:36
Overview - The article discusses the share transfer of Yirui Technology Group Co., Ltd. (奕瑞科技) by its shareholder Hainan Heyi Investment Co., Ltd. (海南合毅) to specific institutional investors, organized by China International Capital Corporation (中金公司) [1] Group 1: Share Transfer Overview - The share transfer is being conducted through a price inquiry process as per relevant regulations [1] - The transfer involves a thorough qualification check of the selling shareholder, Hainan Heyi, by China International Capital Corporation [1] Group 2: Qualification Check Process - The qualification check was completed on June 4, 2025, including verification of business registration documents and ownership proof [2] - Hainan Heyi is registered in Hainan Province with a registered capital of 30 million RMB and has been operational since September 12, 2012 [3] - The company is engaged in investment activities and venture capital, with no legal or regulatory issues affecting its operational status [2][3] Group 3: Compliance with Regulations - The inquiry transfer does not violate any regulations regarding share reduction, as the annual and quarterly reports were announced prior to the transfer [4][5] - The transfer complies with the guidelines set forth by the China Securities Regulatory Commission and the Shanghai Stock Exchange [5][6] - China International Capital Corporation confirms that Hainan Heyi meets all necessary qualifications for participating in the share transfer [6]
奕瑞科技: 奕瑞科技股东询价转让计划书
Zheng Quan Zhi Xing· 2025-06-20 13:29
Key Points - The core point of the announcement is the planned share transfer by Hainan He Yi Investment Co., Ltd. of 6,122,448 shares, representing 3.06% of Yirui Technology's total share capital, through a non-public inquiry transfer [1][2][4] Group 1: Share Transfer Details - The total number of shares to be transferred is 6,122,448, which accounts for 3.06% of Yirui Technology's total share capital [1][2] - The transfer will not be conducted through centralized bidding and the shares cannot be transferred by the acquirer within six months after the acquisition [1][2] - The acquirer must be an institutional investor with appropriate pricing capabilities and risk tolerance [1][3] Group 2: Seller Information - The seller, Hainan He Yi, is not a controlling shareholder or actual controller of Yirui Technology and does not hold more than 5% of the shares [1][2] - Hainan He Yi has confirmed that the shares are free from any transfer restrictions and comply with relevant regulations [1][2] Group 3: Pricing and Transfer Process - The minimum transfer price will be determined based on the guidelines from the Shanghai Stock Exchange and will not be lower than the date of sending the subscription invitation [2][3] - The pricing process will prioritize subscription price, followed by subscription quantity, and then the time of receipt of the subscription forms [3] Group 4: Company Status - Yirui Technology does not have any undisclosed operational risks or circumstances that could lead to a change in control due to this share transfer [4] - There are no other significant undisclosed matters related to the company [4]
奕瑞科技(688301) - 中国国际金融股份有限公司关于奕瑞电子科技集团股份有限公司股东向特定机构投资者询价转让股份相关资格的核查意见
2025-06-20 13:03
中国国际金融股份有限公司 关于奕瑞电子科技集团股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 中国国际金融股份有限公司(以下简称"中金公司")受奕瑞电子科技集团股 份有限公司(以下简称"奕瑞科技,,)股东海南合毅投资有限公司(以下简称 海南 合毅'或"出让方,,)委托,组织实施本次奕瑞科技股东向特定机构投资者询价转让 (以下简称"本次询价转让")。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见)) <<科创 板上市公司持续监管办法(试行))) <<上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 号一一询价转让和配售》 (以下简称" <<询价转让和配售指引)) ")等相关规定,中金公司对参与本次询价 出让方的相关资格进行了核查。 本次询价转让的委托情况、出让方相关资格的核查情况及核查意见如下: 一、本次询价转让概述 2024 11 日,中金公司收到出让方关于本次询价转让的委托,委托中金 公司组织实施本次询价转让。 二、关于参与本次询价转让股东相关资格的核查情况 (一)核查过程 根据相关法规要求,中金公司己于2025 日完成全部出让方相关资格的 ...
奕瑞科技(688301) - 奕瑞科技股东询价转让计划书
2025-06-20 13:01
| 证券代码:688301 | 证券简称:奕瑞科技 | 公告编号:2025-043 | | --- | --- | --- | | 转债代码:118025 | 转债简称:奕瑞转债 | | 奕瑞电子科技集团股份有限公司 股东询价转让计划书 海南合毅投资有限公司保证向奕瑞电子科技集团股份有限公司提供的信息 内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准 确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 拟参与奕瑞电子科技集团股份有限公司(以下简称"奕瑞科技"或"公司") 首发前股东询价转让(以下简称"本次询价转让")的股东为海南合毅投资有限公 司(以下简称"海南合毅"或"出让方")。 出让方拟转让股份的总数为6,122,448股,占奕瑞科技股本比例为3.06%。 本次询价转让为非公开转让,不会通过集中竞价交易方式进行。受让方 通过询价转让受让的股份,在受让后6个月内不得转让。 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 (一)出让方的名称、持股数量、持股比例 出让方委托中国 ...
奕瑞科技(688301) - 奕瑞电子科技集团股份有限公司向不特定对象发行可转换公司债券第三次临时受托管理事务报告(2025年度)
2025-06-18 09:49
股票代码:688301 股票简称:奕瑞科技 债券代码:118025 债券简称:奕瑞转债 奕瑞电子科技集团股份有限公司 向不特定对象发行可转换公司债券 第三次临时受托管理事务报告 (2025 年度) 债券受托管理人 二〇二五年六月 重要声明 本报告依据《公司债券发行与交易管理办法》《关于上海奕瑞光电子科技股 份有限公司向不特定对象发行可转换公司债券之债券受托管理协议》(以下简称 "《受托管理协议》")《上海奕瑞光电子科技股份有限公司向不特定对象发行 可转换公司债券募集说明书》(以下简称"《募集说明书》")等相关规定,由 本次债券受托管理人中国国际金融股份有限公司(以下简称"中金公司")编制。 中金公司对本报告中所包含的从上述文件中引述内容和信息未进行独立验证,也 不就该等引述内容和信息的真实性、准确性和完整性做出任何保证或承担任何责 任。 本报告不构成对投资者进行或不进行某项行为的推荐意见,投资者应对相关 事宜做出独立判断,而不应将本报告中的任何内容据以作为中金公司所作的承诺 或声明。在任何情况下,投资者依据本报告所进行的任何作为或不作为,中金公 司不承担任何责任。 1 中国国际金融股份有限公司作为奕瑞电子科技 ...
奕瑞科技: 奕瑞电子科技集团股份有限公司向不特定对象发行可转换公司债券第三次临时受托管理事务报告(2025年度)
Zheng Quan Zhi Xing· 2025-06-17 10:29
Core Viewpoint - The report outlines the issuance of convertible bonds by Yirui Technology, detailing the bond's characteristics, terms, and the management of the bondholder's rights by China International Capital Corporation (CICC) [2][3][9] Group 1: Bond Issuance Overview - The bond issuance was approved by the company's board on January 13, 2022, and by the shareholders on February 15, 2022, with a validity period until February 14, 2023 [3] - The China Securities Regulatory Commission approved the bond registration on September 15, 2022 [3] Group 2: Bond Details - The bond is named "Yirui Convertible Bonds" with a code of 118025, issued at a scale of RMB 1,435.01 million, consisting of 14,350,100 bonds [3][4] - The bonds have a face value of RMB 100 each and are issued at par [4] - The bond has a six-year term from October 24, 2022, to October 23, 2028, with a tiered interest rate starting from 0.2% in the first year to 2.0% in the sixth year [4][5] Group 3: Conversion and Pricing - The conversion period for the bonds starts on April 28, 2023, and ends on October 23, 2028, with an initial conversion price of RMB 499.89 per share, adjusted to RMB 162.64 per share [5][6] - Following a profit distribution and capital increase plan, the conversion price was adjusted to RMB 115.50 per share effective June 19, 2025 [8] Group 4: Credit Rating and Management - The bonds received a credit rating of AA from Dongfang Jincheng International Credit Rating Co., Ltd., with a stable outlook [6] - CICC, as the bond's trustee, will monitor significant matters affecting bondholders' rights and ensure compliance with relevant regulations [9]
华安证券:首次覆盖奕瑞科技给予买入评级
Zheng Quan Zhi Xing· 2025-06-15 10:04
Core Viewpoint - The report highlights Yirui Technology as a leading domestic digital X-ray detector manufacturer, emphasizing its comprehensive product matrix and significant market share in the global landscape [2][5]. Product and Market Position - Yirui Technology has developed over 100 types of digital X-ray detectors, covering various medical and industrial applications, with a shipment increase from 67,000 units in 2021 to 105,500 units in 2023, representing a compound annual growth rate (CAGR) of over 25% [2]. - The company accounted for 20.09% of the global digital X-ray detector shipments in 2023, with a total global shipment forecast of 525,300 units [2]. Business Expansion and Growth Potential - The company is expanding into the core components and overall solutions market, with projected revenue from core components reaching 126 million yuan in 2024, a year-on-year growth of approximately 45.5% [3]. - The overall solutions segment is expected to generate around 96 million yuan in 2024, reflecting a staggering year-on-year growth of 262.56% [3]. - The company has initiated projects for medical DR, C-arm, and CT products, with an anticipated production value of nearly 5 billion yuan by 2030 [3]. Core Component Market Opportunity - The global tube market is projected to grow from $4.26 billion in 2023 to $9.53 billion by 2030, with a CAGR of 12.18% [4]. - Yirui Technology has begun developing various types of tubes since 2022, with some products nearing mass production and achieving international advanced standards [4]. Financial Projections - Revenue forecasts for Yirui Technology are expected to reach 2.266 billion yuan, 3.100 billion yuan, and 4.133 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 23.7%, 36.8%, and 33.3% [5]. - Net profit projections for the same years are 597 million yuan, 790 million yuan, and 1.044 billion yuan, with growth rates of 28.3%, 32.3%, and 32.2% [5].